Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14/S7B updates)

DG Strauss, WW Wu, Z Li, J Koerner… - Clinical Pharmacology …, 2021 - Wiley Online Library
After multiple drugs were removed from the market secondary to drug‐induced torsade de
pointes (TdP) risk, the International Council for Harmonisation (ICH) released guidelines in …

The 'Digital Twin'to enable the vision of precision cardiology

J Corral-Acero, F Margara, M Marciniak… - European heart …, 2020 - academic.oup.com
Providing therapies tailored to each patient is the vision of precision medicine, enabled by
the increasing ability to capture extensive data about individual patients. In this position …

Creation and application of virtual patient cohorts of heart models

SA Niederer, Y Aboelkassem… - … of the Royal …, 2020 - royalsocietypublishing.org
Patient-specific cardiac models are now being used to guide therapies. The increased use
of patient-specific cardiac simulations in clinical care will give rise to the development of …

Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative

Z Li, BJ Ridder, X Han, WW Wu, J Sheng… - Clinical …, 2019 - Wiley Online Library
The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are
sensitive but not specific for predicting which drugs are pro‐arrhythmic. In response, the …

[HTML][HTML] Machine learning in drug development: Characterizing the effect of 30 drugs on the QT interval using Gaussian process regression, sensitivity analysis, and …

FS Costabal, K Matsuno, J Yao, P Perdikaris… - Computer Methods in …, 2019 - Elsevier
Prolonged QT intervals are a major risk factor for ventricular arrhythmias and a leading
cause of sudden cardiac death. Various drugs are known to trigger QT interval prolongation …

Comprehensive in vitro proarrhythmia assay (CiPA) update from a cardiac safety research consortium/health and environmental sciences institute/FDA meeting

DG Strauss, G Gintant, Z Li, W Wu… - Therapeutic …, 2019 - journals.sagepub.com
A Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/FDA-
sponsored Think Tank Meeting was convened in Washington, DC, on May 21, 2018, to bring …

Prediction of arrhythmia susceptibility through mathematical modeling and machine learning

M Varshneya, X Mei, EA Sobie - Proceedings of the …, 2021 - National Acad Sciences
At present, the QT interval on the electrocardiographic (ECG) waveform is the most common
metric for assessing an individual's susceptibility to ventricular arrhythmias, with a long QT …

Comprehensive uncertainty quantification and sensitivity analysis for cardiac action potential models

P Pathmanathan, JM Cordeiro, RA Gray - Frontiers in physiology, 2019 - frontiersin.org
Recent efforts to ensure the reliability of computational model-based predictions in
healthcare, such as the ASME V&V40 Standard, emphasize the importance of uncertainty …

Drug‐induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias

E Passini, C Trovato, P Morissette… - British journal of …, 2019 - Wiley Online Library
Background and Purpose Early identification of drug‐induced cardiac adverse events is key
in drug development. Human‐based computer models are emerging as an effective …

[HTML][HTML] Digital twinning of the human ventricular activation sequence to Clinical 12-lead ECGs and magnetic resonance imaging using realistic Purkinje networks for …

J Camps, LA Berg, ZJ Wang, R Sebastian… - Medical Image …, 2024 - Elsevier
Cardiac in silico clinical trials can virtually assess the safety and efficacy of therapies using
human-based modelling and simulation. These technologies can provide mechanistic …